Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Ruby Khatun Khatun
    Ruby Khatun Khatun
      • Home
      • Ruby Khatun Khatun

      Articles By : Ruby Khatun Khatun

      AstraZeneca sees pivotal lung cancer trial results later in 2018

      AstraZeneca sees pivotal lung cancer trial results later in 2018

      Ruby Khatun Khatun13 March 2018 10:00 AM IST
      LONDON: AstraZeneca now expects a key lung cancer study of two immunotherapy drugs to produce overall survival results in the second half of 2018,...
      Biogen to buy Pfizers neurology drug in deal nearing 600 million dollars

      Biogen to buy Pfizer's neurology drug in deal nearing 600 million dollars

      Ruby Khatun Khatun13 March 2018 9:45 AM IST
      Biogen Inc said on Monday it would buy Pfizer Inc’s experimental treatment for a symptom associated with schizophrenia in a deal that could near $600...
      Reckitt CEO stands by Mead Johnson deal, despite Pfizer option

      Reckitt CEO stands by Mead Johnson deal, despite Pfizer option

      Ruby Khatun Khatun13 March 2018 9:30 AM IST
      LONDON: Reckitt Benckiser has no regrets about its $17 billion acquisition of Mead Johnson last year, its chief executive said, even though there are...
      Claris Lifesciences shares to delist on March 22

      Claris Lifesciences shares to delist on March 22

      Ruby Khatun Khatun13 March 2018 9:06 AM IST
      New Delhi: Claris Lifesciences on Monday announced the delisting of Equity shares from the BSE with effect from March 22, 2018, while the...
      Infestation alert: USFDA finds Female Mosquito at Aurobindo Pharma facility

      Infestation alert: USFDA finds Female Mosquito at Aurobindo Pharma facility

      Ruby Khatun Khatun12 March 2018 11:18 AM IST
      New Delhi: US Food and Drug Administration officials found a 'large female mosquito' in a facility of Aurobindo Pharma during the inspection, which,...
      Neuberg Diagnostics to invest Rs 300 crore for expansion

      Neuberg Diagnostics to invest Rs 300 crore for expansion

      Ruby Khatun Khatun12 March 2018 10:30 AM IST
      Mumbai: Neuberg Diagnostics, an alliance of five leading pathology laboratories from India, South Africa and the UAE, is planning to invest Rs 300...
      Translumina eyes 25 percent of stents market by 2018-end

      Translumina eyes 25 percent of stents market by 2018-end

      Ruby Khatun Khatun12 March 2018 10:15 AM IST
      New Delhi: Domestic medical devices maker Translumina Therapeutics is eyeing a 25 percent share in the Indian stents market by the 2018-end as it...
      Sterling biotech case: ED files charge sheet against ex-Andhra bank official

      Sterling biotech case: ED files charge sheet against ex-Andhra bank official

      Ruby Khatun Khatun12 March 2018 10:00 AM IST
      New Delhi: The Enforcement Directorate filed a charge sheet against a former Andhra Bank director in an alleged Rs 5,000-crore bank fraud case...
      Regeneron, Sanofi offer new Praluent pricing to break reimbursement logjam

      Regeneron, Sanofi offer new Praluent pricing to break reimbursement logjam

      Ruby Khatun Khatun12 March 2018 9:45 AM IST
      Regeneron Pharmaceuticals Inc and Sanofi SA said on Saturday they would be willing to charge less for their potent cholesterol drug, Praluent if...
      Labeling Norms For Generic Drugs: Health Minister apprises parliament

      Labeling Norms For Generic Drugs: Health Minister apprises parliament

      Ruby Khatun Khatun11 March 2018 11:56 AM IST
      New Delhi: The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about the...
      Amazon isnt only retail giant trying to remake healthcare: Report

      Amazon isn't only retail giant trying to remake healthcare: Report

      Ruby Khatun Khatun11 March 2018 10:30 AM IST
      Amazon.com Inc. says it wants to remake health care for its workers. But its biggest rival is beating it to the punch.Walmart Inc., the largest...
      GSK gets EU approval for labelling update to Relvar Ellipta for asthma

      GSK gets EU approval for labelling update to Relvar Ellipta for asthma

      Ruby Khatun Khatun11 March 2018 10:15 AM IST
      London: GlaxoSmithKline plc (GSK) and Innoviva, Inc. announced that the European Commission has approved a label update for the use of once-daily...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok